A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(34 sites) United States
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California Yale Cancer Center, New Haven, Connecticut Mayo Clinic Rochester, Rochester, Minnesota Md Anderson Cancer Center, Houston, Texas Fred Hutchinson Cancer Research Center, Seattle, Washington University of Wisconsin, Madison, Wisconsin Australia
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales Liverpool Hospital, Liverpool, New South Wales Icon Cancer Centre South Brisbane, South Brisbane, Queensland Monash Health, Clayton, Victoria Cabrini Hospital Malvern, Malvern East, Victoria China
Beijing Cancer Hospital, Beijing, Beijing Municipality The Tumor Hospital Affiliated to Guangxi Medical Universitywuxiang Branch, Nanning, Guangxi Harbin Medical University Cancer Hospital, Harbin, Heilongjiang The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan Henan Cancer Hospital, Zhengzhou, Henan Hubei Cancer Hospital, Wuhan, Hubei Affiliated Hospital of Jiangnan University South Campus, Wuxi, Jiangsu The Affiliated Hospital of Xuzhou Medical University Kunpeng Road Branch, Xuzhou, Jiangsu The Affiliated Hospital of Qingdao University Branch North, Qingdao, Shandong The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong Affiliated Zhongshan Hospital of Fudan University, Shanghai, Shanghai Municipality Shanghai East Hospital Branch Hospital, Shanghai, Shanghai Municipality
South Korea
Cha Bundang Medical Center, Cha University, BundangGu SeongnamSi, Gyeonggi-do Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do Kyungpook National University Chilgok Hospital, BukGu, Gyeongsangbukdo Gachon University Gil Medical Center, NamdongGu, Incheon Gwang'yeogsi Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi Seoul National University Hospital, Seoul, Seoul Teugbyeolsi Gangnam Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi Asan Medical Center, SongpaGu, Seoul Teugbyeolsi
Key details Enrollment target
~168 participants
Primary completion
December 2026
Age range
18 Years and older
Last updated April 2026
Interested in joining? Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan